Dr Fatima Cardoso talks to ecancer at the ESMO 2018 congress in Munich about the latest in breast cancer research reported at the conference.

She highlights the results from SOLAR-1, IMpassion130, and PALOMA-3 as important, and reflects on the need for trial designs with overall survival as a co-endpoint from the outset.

Dr Cardoso also discusses the impact of CDK inhibitors on breast cancer care, and how research in disease progression after CDK therapy is required.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.